PMIYX
Price
$10.72
Change
-$0.06 (-0.56%)
Updated
Feb 21 closing price
Net Assets
228.17M
VASIX
Price
$15.28
Change
-$0.00 (-0.00%)
Updated
Feb 21 closing price
Net Assets
3.93B
Ad is loading...

PMIYX vs VASIX

Header iconPMIYX vs VASIX Comparison
Open Charts PMIYX vs VASIXBanner chart's image
Putnam Multi-Asset Income Y
Price$10.72
Change-$0.06 (-0.56%)
VolumeN/A
Net Assets228.17M
Vanguard LifeStrategy Income I
Price$15.28
Change-$0.00 (-0.00%)
VolumeN/A
Net Assets3.93B
PMIYX vs VASIX Comparison Chart
Loading...
View a ticker or compare two or three
VS
PMIYX vs. VASIX commentary
Feb 22, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PMIYX is a Buy and VASIX is a Hold.

Ad is loading...
FUNDAMENTALS
Fundamentals
VASIX has more cash in the bank: 3.93B vs. PMIYX (228M). VASIX (3.30) and PMIYX (3.17) have matching dividends . PMIYX was incepted earlier than VASIX: PMIYX (2 years) vs VASIX (30 years). PMIYX is a more actively managed with annual turnover of: 109.00 vs. VASIX (4.00). PMIYX has a lower initial minimum investment than VASIX: PMIYX (0) vs VASIX (3000). PMIYX annual gain was more profitable for investors over the last year : 10.91 vs. VASIX (4.54).
PMIYXVASIXPMIYX / VASIX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence2 years30 years-
Gain YTD2.0311.530133%
Front LoadN/AN/A-
Min. Initial Investment03000-
Min. Initial Investment IRAN/AN/A-
Net Assets228M3.93B6%
Annual Yield % from dividends3.173.3096%
Returns for 1 year10.914.54240%
Returns for 3 yearsN/A0.64-
Returns for 5 yearsN/A1.96-
Returns for 10 years15.3923.6565%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SHLS4.590.26
+6.00%
Shoals Technologies Group
COKE1442.6532.93
+2.34%
Coca-Cola Consolidated
JZXN4.830.02
+0.42%
Jiuzi Holdings Inc.
TM180.680.58
+0.32%
Toyota Motor Corp
RGLS1.27-0.03
-2.31%
Regulus Therapeutics